Frontiers in Clinical Drug Research CNS and Neurological Disorders Volume 4 1st Edition by Atta Ur Rahman ISBN 1681082969 9781681082950

Frontiers in Clinical Drug Research CNS and Neurological Disorders Volume 4 1st Edition by Atta Ur Rahman  – Ebook PDF Instant Download/Delivery: 1681082969 ,9781681082950
Full download Frontiers in Clinical Drug Research CNS and Neurological Disorders Volume 4 1st Edition after payment

Product details:

ISBN 10: 1681082969
ISBN 13: 9781681082950
Author: Atta Ur Rahman

Frontiers in Clinical Drug Research CNS and Neurological Disorders Volume 4 1st Edition Table of contents:

I. INTRODUCTION

I.1. Background

I.2. Alzheimer’s Disease and the Need for New Drugs

I.3. The Amyloid Cascade Hypothesis (ACH)

I.4. Correlation among Aβ and other AD Hallmarks

I.5. Genetics of AD

I.5.1. APP

I.5.2. PSEN1/PSEN2

I.5.3. APOE

I.5.4 . APOJ/CLU

I.5.5. The Role of Genetic Testing in Clinical Care

II. THE ROLE OF BIOMARKERS IN EARLY DIAGNOSIS AND CLINICAL TRIALS ASSESSMENT

II.1. Biochemical Markers

II.1.1. Cerebrospinal Fluid Biomarkers

II.1.2. Blood Biomarkers

II.2. Imaging-based Biomarkers

II.2.1. Structural Magnetic Resonance Imaging

II.2.2. Diffusion Tensor Imaging

II.2.3. Functional Magnetic Resonance Imaging

II.2.4. Proton Magnetic Resonance Spectroscopy

II.2.5. Fluorodeoxyglucose-Positron Emission Tomography

II.2.6. Amyloid-Positron Emission Tomography

II.3. The Continuum of AD: Diagnosis and Prognosis

II.4. Regulatory Framework

III. PROSPECTIVE THERAPIES

III.1. Non-immunologic Therapies

III.1.1. Clinical Trials

III.1.2. Preclinical Studies

III.2. Immunotherapy

III.2.1. Active Immunotherapy

III.2.2. Passive Immunotherapy

CONCLUSION AND FUTURE PERSPECTIVES

CONFLICT OF INTEREST

FUNDING

ACKNOWLEDGMENTS

REFERENCES

At the Crossroad between Neuronal Hyperexcitability and Neuroinflammation: New Therapeutic Opportuni

INTRODUCTION

1. BACKGROUND ON AD

1.1. APP Processing

1.2. Genetics of AD

1.3. Clinical Trials & Treatment Strategies

2. PRECLINICAL AVENUES

2.1. Neuroinflammation & Tumor Necrosis Factor-α

2.2. Network Hyperexcitability

3. CROSS-TALK   BETWEEN   SYNAPTIC   HYPEREXCITABILITY   & TNF

CONCLUSION

CONFLICT OF INTEREST

ACKNOWLEDGEMENTS

FUNDING

REFERENCES

Treatment of Diabetic Neuropathy – Current Possibilities and Perspectives

INTRODUCTION

DIABETES MELLITUS

CHRONIC COMPLICATIONS OF DIABETES MELLITUS

DIABETIC NEUROPATHY

ETIOPATHOGENESIS OF DIABETIC NEUROPATHY

Advanced Glycation End Products

Oxidative Stress

Gene Polymorphisms Of Antioxidant Enzymes And Chronic Diabetic Complications

Polyol Pathway

Protein Kinase C

Hexosamine Pathway

Low C-peptide Concentration

Proinflammatory Cytokines

Neurotrophic Factors

Angiotensin-converting Enzyme

Kinin B1 Receptor

TREATMENT OF DIABETIC NEUROPATHY

Treatment of Diabetes Mellitus – Adequate Compensation

Supportive and Additional Treatment

Alpha-lipoic Acid

Symptomatic Treatment

Treatment in Experimental and Clinical Studies

Anti-inflammatory Drugs

Neurotrophic Factors

Angiotensin Converting enzyme (ACE) Inhibitors

Novel Drugs with Antioxidant Functions

Non-pharmacological Therapy

inhibitors of Epigenetic Modifications

CONCLUSION

CONFLICT OF INTEREST

ACKNOWLEDGEMENT

REFERENCES

The Now and Tomorrow of Migraine Treatments

INTRODUCTION

PATHOPHYSIOLOGICAL OVERVIEW

ACUTE ATTACK TREATMENT

Currently Available Drugs

Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

Ergot Alkaloids and Triptans

Combination Regimens

Narcotic Analgesics

Hyperbaric Oxygen Therapy

Medication Overuse Headache

Novel Targets for Attack Treatment

CGRP

NOS Inhibition

TRP Channels

Glutamate Receptors

PACAP-38

Cannabinoids

The Parenchymal Inflammatory Cascade

PROPHYLACTIC TREATMENT

Currently Available Drugs

Antiepileptics

Antidepressants

Beta Blockers

Calcium Channel Blockers

Glutamate Receptor Antagonists

Triptans

Novel Targets for Prophylactic Treatment

CGRP

NOS Inhibition

Gap Junction Blockers

Renin-Angiotensin System

Acid Sensing Ion Channels

Botulinum Neurotoxin

CONCLUDING REMARKS

CONFLICT OF INTEREST

ACKNOWLEDGEMENTS

REFERENCES

The Now and Tomorrow of Ischemic Stroke Treatment

ADVANCES IN TREATMENT OF ACUTE ISCHEMIC STROKE

Recanalization/Reperfusion

Neuro-Glial Protection

Prevention of Secondary Complications

ADVANCES IN SECONDARY PROPHYLAXIS OF ISCHEMIC STROKE

CONCLUDING REMARKS

CONFLICT OF INTEREST

ACKNOWLEDGEMENTS

REFERENCES

SUBJECT INDEX

People also search for Frontiers in Clinical Drug Research CNS and Neurological Disorders Volume 4 1st Edition:

    
what is a clinical research facility
    
types of clinical trials
    
frontiers clinical trials
    
frontiers in drug discovery
    
frontiers in drug safety and regulation

Tags: Atta Ur Rahman, Clinical Drug Research, Neurological Disorders